AI Article Synopsis
Article Abstract
Purpose: Patients with succinate dehydrogenase subunit B(SDHB) mutation-related pheochromocytoma/paraganglioma (PHEO/PGL) are at a higher risk for metastatic disease than other hereditary PHEOs/PGLs. Current therapeutic approaches are limited, but the best outcomes are based on the early and proper detection of as many lesions as possible. Because PHEOs/PGLs overexpress somatostatin receptor 2 (SSTR2), the goal of our study was to assess the clinical utility of [(68)Ga]-DOTA(0)-Tyr(3)-octreotate ([(68)Ga]-DOTATATE) positron emission tomography/computed tomography (PET/CT) and to evaluate its diagnostic utility in comparison with the currently recommended functional imaging modalities [(18)F]-fluorodopamine ([(18)F]-FDA), [(18)F]-fluorodihydroxyphenylalanine ([(18)F]-FDOPA), [(18)F]-fluoro-2-deoxy-d-glucose ([(18)F]- FDG) PET/CT as well as CT/MRI.
Experimental Design: [(68)Ga]-DOTATATE PET/CT was prospectively performed in 17 patients with SDHB-related metastatic PHEOs/PGLs. All patients also underwent [(18)F]-FDG PET/CT and CT/MRI, with 16 of the 17 patients also receiving [(18)F]-FDOPA and [(18)F]-FDA PET/CT scans. Detection rates of metastatic lesions were compared between all these functional imaging studies. A composite synthesis of all used functional and anatomical imaging studies served as the imaging comparator.
Results: [(68)Ga]-DOTATATE PET/CT demonstrated a lesion-based detection rate of 98.6% [95% confidence interval (CI), 96.5%-99.5%], [(18)F]-FDG, [(18)F]-FDOPA, [(18)F]-FDA PET/CT, and CT/MRI showed detection rates of 85.8% (CI, 81.3%-89.4%; P < 0.01), 61.4% (CI, 55.6%-66.9%; P < 0.01), 51.9% (CI, 46.1%-57.7%; P < 0.01), and 84.8% (CI, 80.0%-88.5%; P < 0.01), respectively.
Conclusions: [(68)Ga]-DOTATATE PET/CT showed a significantly superior detection rate to all other functional and anatomical imaging modalities and may represent the preferred future imaging modality in the evaluation of SDHB-related metastatic PHEO/PGL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558308 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-14-2751 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Head-to-Head Comparison of 68Ga-DOTATATE and 18F-FDG PET in EBV-Positive Nonkeratinizing Nasopharyngeal Carcinoma.
Clin Nucl Med
December 2024
From the Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Purpose: The aim of this study was to compare the clinical application value of 68Ga-DOTATATE and 18F-FDG PET/CT in Epstein-Barr virus (EBV)-positive nonkeratinizing nasopharyngeal carcinoma.
Patients And Methods: Patients underwent 18F-FDG and 68Ga-DOTATATE PET scans. The lesion numbers, tracer parameters, and primary tumor volume derived from contrast-enhanced MRI, 18F-FDG, and 68Ga-DOTATATE PET were compared.
Pineal Gland Activity in Advanced-Stage Pediatric Neuroblastoma Patients on 68Ga-DOTATATE PET/CT.
Clin Nucl Med
December 2024
From the Department of Nuclear Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Neuroblastoma is the most common malignancy in infants and the most common extracranial solid tumor accounting for approximately 6% of pediatric cancer. Although surgical intervention serves as the primary treatment for early-stage disease, advanced-stage cases necessitate a variety of oncologic therapeutic approaches, including 131I-MIBG and peptide receptor radionuclide therapy. Herein we report incidental pineal gland activity, represented in 68Ga-DOTATATE PET/CT (SSTR-PET) in 3 pediatric patients diagnosed with stage 4 neuroblastoma, related to the physiological distribution of radiopharmaceuticals.
View Article and Find Full Text PDFEstimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Eur Heart J Cardiovasc Imaging
December 2024
Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection. Traditional biomarkers of inflammation, such as high-sensitivity C-reactive protein (hsCRP), show an association with cardiovascular risk on a population level, but do not have specificity for local plaque inflammation.
View Article and Find Full Text PDF68Ga-DOTATATE PET/CT Demonstrated More Lesions of Leptomeningeal Metastases Compared With 123I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.
Clin Nucl Med
December 2024
From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.
A 5-year-old girl with high-risk neuroblastoma after therapy was evaluated by 123I-MIBG SPECT/CT and 68Ga-DOTATATE PET/CT. Contrast-enhancement brain MRI demonstrated 2 metastatic lesions in the right parietal lobe of brain. One lesion showed abnormal MIBG accumulation associated with high density in the right central posterior gyrus, whereas the other lesion did not show MIBG uptake.
View Article and Find Full Text PDFRemission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.
BMJ Case Rep
November 2024
Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
A patient with a long history of bone predominant, metastatic paraganglioma who had multiple episodes of progressive disease despite prior treatments demonstrated a remarkable disease response to zoledronic acid. After 1 year of treatment, there was a complete resolution of lymphadenopathy and disappearance of all somatostatin receptor avid lesions by positron emission tomography-CT and radiopharmaceutical Gallium Ga 68 Dotatate. Stability of disease was further demonstrated by CT over several years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!